182 related articles for article (PubMed ID: 35864858)
1. A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm.
Dong A; Pan X; Lin CW; Huang YW; Krause H; Pan P; Baim A; Thomas MJ; Chen X; Yu J; Michaelis L; Liu P; Wang LS; Atallah E
J Cancer Prev; 2022 Jun; 27(2):129-138. PubMed ID: 35864858
[TBL] [Abstract][Full Text] [Related]
2. Effects of Black Raspberry Supplementation on Methylation Pathways in
Dong A; Huang YW; Niu B; Liu R; Wu W; Gao H; Yu J; Wang LS
J Cancer Prev; 2023 Dec; 28(4):212-218. PubMed ID: 38205364
[TBL] [Abstract][Full Text] [Related]
3. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents.
Huang L; Garcia-Manero G; Jabbour E; Goswami M; Routbort MJ; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2016 Apr; ():. PubMed ID: 27083210
[TBL] [Abstract][Full Text] [Related]
4. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
5. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Duong VH; Al Ali N; Zhang L; Padron E; Sallman D; Lancet JE; List AF; Komrokji RS
Leuk Lymphoma; 2020 Aug; 61(8):1901-1907. PubMed ID: 32306798
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract][Full Text] [Related]
8. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
9. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.
Karantanos T; Tsai HL; Gondek LP; DeZern AE; Ghiaur G; Dalton WB; Gojo I; Prince GT; Webster J; Ambinder A; Smith BD; Levis MJ; Varadhan R; Jones RJ; Jain T
Leuk Lymphoma; 2022 Aug; 63(8):1942-1948. PubMed ID: 35379077
[TBL] [Abstract][Full Text] [Related]
10. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
11. An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.
Islam A
Clin Case Rep; 2023 Aug; 11(8):e7748. PubMed ID: 37546162
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
Komrokji R; Melody M; Al Ali N; Chan O; Klimek V; Ball BJ; Sekeres MA; Lucas G; Maciejewski JP; Sallman DA; Padron E; Kuykendall A; Lasho T; Al-Kali A; Naqvi K; Steensma DP; Garcia-Manero G; Patnaik MM
Leuk Lymphoma; 2022 Jan; 63(1):199-204. PubMed ID: 34448437
[TBL] [Abstract][Full Text] [Related]
13. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernández-Boluda JC; Martínez-Cuadrón D; Pereira A; Rodríguez-Veiga R; Boluda B; Gil C; Casal-Marini S; Serrano J; Martínez-López J; Bergua J; Algarra L; Bernal T; López-Lorenzo JL; Colorado M; López A; Tormo M; Sayas MJ; Trigo F; López-Pavía M; Pérez-Simón JA; Lavilla-Rubira E; Rodríguez-Medina C; Rodríguez-Gutiérrez JI; Sanz-Caballer MA; Montesinos P;
Leuk Res; 2022 Apr; 115():106821. PubMed ID: 35286939
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
15. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
[TBL] [Abstract][Full Text] [Related]
16. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
Gerke MB; Christodoulou I; Karantanos T
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib study of the effects of black raspberries on rectal polyps in patients with familial adenomatous polyposis.
Wang LS; Burke CA; Hasson H; Kuo CT; Molmenti CL; Seguin C; Liu P; Huang TH; Frankel WL; Stoner GD
Cancer Prev Res (Phila); 2014 Jul; 7(7):666-74. PubMed ID: 24764585
[TBL] [Abstract][Full Text] [Related]
19. [Markers for Predicting Response to Hypomethylating Agents in MDS and AML Patients].
Chen XP; Jing Y; Li YH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1769-73. PubMed ID: 26708908
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]